Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide in Alzheimer's Disease
NCT06052163Phase 2Recruiting
- Sponsor
- Stanford University
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bumetanide in Alzheimer's disease (AD) (3 arms), sponsored by Stanford University. Primary endpoint: Incidence of Treatment-Related Adverse Events at 6 months. Started Apr 2023; status: recruiting.
02
Drugs
bumetanide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06052163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06052163.